Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (211-220 of 280) with videos related to

Pageof 28
Sort By:
Hepatology (Baltimore, Md.)|July 18, 2017
MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in miceHeng Wu, Junyan Tao, Xiaolei Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2022
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)Hongyan Li, Menghan Gao, Hailong You, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|August 4, 2015
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study]Xinyue Chen, Jia Shang, Ruifeng Yang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 31, 2019
Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue TherapyRong Fan, Bin Zhou, Min Xu, et al.
Journal of Hepatology|May 31, 2016
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled studyJian Sun, Hong Ma, Qing Xie, et al.
Journal of Gastroenterology and Hepatology|June 12, 2016
Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos studyHui-Ying Rao, Hong Li, Hong Chen, et al.
Journal of Hepatology|October 18, 2025
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responsesHongfeng Yuan, Lina Zhao, Guang Yang, et al.
BMC Gastroenterology|November 20, 2020
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trialJieting Tang, Yongfeng Wang, Tao Han, et al.
Hepatology (Baltimore, Md.)|September 30, 2017
A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinomaPing Luo, Peiyuan Yin, Rui Hua, et al.
Scandinavian Journal of Public Health|May 3, 2018
China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis BShan Shan, Wei Wei, Yuanyuan Kong, et al.
Pageof 28

Showing results (211-220 of 280) with videos related to

Sort By:
Pageof 28
Hepatology (Baltimore, Md.)|July 18, 2017
MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in miceHeng Wu, Junyan Tao, Xiaolei Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2022
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)Hongyan Li, Menghan Gao, Hailong You, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|August 4, 2015
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study]Xinyue Chen, Jia Shang, Ruifeng Yang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 31, 2019
Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue TherapyRong Fan, Bin Zhou, Min Xu, et al.
Journal of Hepatology|May 31, 2016
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled studyJian Sun, Hong Ma, Qing Xie, et al.
Journal of Gastroenterology and Hepatology|June 12, 2016
Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos studyHui-Ying Rao, Hong Li, Hong Chen, et al.
Journal of Hepatology|October 18, 2025
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responsesHongfeng Yuan, Lina Zhao, Guang Yang, et al.
BMC Gastroenterology|November 20, 2020
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trialJieting Tang, Yongfeng Wang, Tao Han, et al.
Hepatology (Baltimore, Md.)|September 30, 2017
A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinomaPing Luo, Peiyuan Yin, Rui Hua, et al.
Scandinavian Journal of Public Health|May 3, 2018
China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis BShan Shan, Wei Wei, Yuanyuan Kong, et al.
Pageof 28